// App-Quantinova.ai

4718 : ABBV-075, a novel BET family bromodomain inhibitor, represents a promising therapeutic agent for a broad spectrum of cancer indications

Researchers

Presenter

  • Aparna Sarthy

Principal Investigators

  • Daniel H. Albert

  • Xiaoyu Lin

  • Warder Scott

  • Emily Faivre

  • Mai H. Bui

  • Xiaoli Huang

  • Denise M. Wilcox

  • Terry Magoc

  • Fritz G. Buchanan

  • Paul Tapang

  • George S. Sheppard

  • Le Wang

  • Steve D. Fidanze

  • John Pratt

  • Dachun Liu

  • Lisa Hasvold

  • Paul Hessler

  • Tamar Uziel

  • Lloyd Lam

  • Ganesh Rajaraman

  • Guowei Fang

  • Steven W. Elmore

  • Saul H. Rosenberg

  • Keith McDaniel

  • Warren Kati

  • Yu Shen

Medical Centers

  • AbbVie, Inc., North Chicago, IL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Hematological malignancies

  • Small cell lung cancer

  • Multiple Myeloma

  • B cell lymphomas

  • Lung Cancer

  • Solid malignancies

  • Lymphomas

Biomarkers

  • CREB-binding protein

Drug/Treatment

  • abbv-075

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved